title: Intra-arterial thrombolysis within three hours of stroke onset in middle cerebral artery strokes.
abstract: OBJECTIVE
  The Prolyse in Acute Cerebral Thromboembolism II (PROACT II) trial showed improved outcomes in patients with proximal middle cerebral artery (MCA) occlusions treated with intra-arterial (IA) thrombolysis within 6 h of stroke onset. We analyzed outcomes of patients with proximal MCA occlusions treated within 3 h of stroke onset in order to determine the influence of time-to-treatment on clinical and angiographic outcomes in patients receiving IA thrombolysis.
  
  
  METHODS
  Thirty-five patients from three academic institutions with angiographically demonstrated proximal MCA occlusions were treated with IA thrombolytics within 3 h of stroke onset. Outcome measures included outcomes at 30-90 day follow-up, recanalization rates, incidence of symptomatic intracranial hemorrhage, and mortality in the first 90 days. The endpoints were compared to the IA treated and control groups of the PROACT II trial.
  
  
  RESULTS
  The median admission National Institutes of Health Stroke Scale (NIHSS) score was 16 (range 4-24). The mean time to initiation of treatment was 106 min (range 10-180 min). Sixty-six percent of patients treated, had a modified Rankin Scale (mRS) score of 2 or less at 1-3 month follow-up compared to 40% in the PROACT II trial. The recanalization rate was 77% (versus 66% in PROACT II). The symptomatic intracranial hemorrhage rate was 11% (versus 10% in PROACT II) and the mortality rate was 23% (versus 25% in PROACT II).
  
  
  CONCLUSIONS
  Time-to-treatment is just as important in IA thrombolysis as it is in IV thrombolysis, both for improving clinical outcomes and recanalization rates as well.
authors.affiliation: Department of Radiology and Neurology, College of Medicine, The Ohio State University Medical Center, 623 Means Hall, 1654 Upham Dr., Columbus, OH 43210, USA. eric.bourekas@osumc.edu
authors.forename: Eric C
authors.initials: EC
authors.lastname: Bourekas
authors.forename: Andrew
authors.initials: A
authors.lastname: Slivka
authors.forename: Rajul
authors.initials: R
authors.lastname: Shah
authors.forename: Yousef
authors.initials: Y
authors.lastname: Mohammad
authors.forename: H Wayne
authors.initials: HW
authors.lastname: Slone
authors.forename: Dimitris T
authors.initials: DT
authors.lastname: Kehagias
authors.forename: Jose
authors.initials: J
authors.lastname: Suarez
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Sunshine
authors.forename: Osama O
authors.initials: OO
authors.lastname: Zaidat
authors.forename: Robert
authors.initials: R
authors.lastname: Tarr
authors.forename: Dennis M
authors.initials: DM
authors.lastname: Landis
authors.forename: M Fareed K
authors.initials: MF
authors.lastname: Suri
authors.forename: Adnan I
authors.initials: AI
authors.lastname: Qureshi
mesh_terms: D000368:Aged; D002533:Cerebral Angiography; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D020244:Infarction, Middle Cerebral Artery / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D020768:Middle Cerebral Artery / Q000000981:diagnostic imaging* / Q000187:drug effects; D016017:Odds Ratio; D010348:Patient Care Team; D016019:Survival Analysis; D017741:Survivors; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents